We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

By LabMedica International staff writers
Posted on 09 Nov 2022

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. More...

(San Diego, CA, USA), which provides multiplex staining panels, tissue staining, and imaging and analysis services.

Cell IDx's UltraPlex technology allows simultaneous detection of multiple biomarkers in many immunoassays through fluorescent and chromogenic multiplex immunohistochemistry (IHC) staining technology, and automated chromogenic detection of multiple markers on Leica Biosystems' BOND RX fully automated research stainer. Together, UltraPlex and BOND RX with high throughput imaging allows researchers to detect three or more markers chromogenically on a single slide using a straightforward pathology workflow. In 2021, Leica Biosystems and Cell IDx had announced a partnership to combine the benefits of UltraPlex and BOND RX; now, Leica Biosystems has acquired Cell IDx, advancing this partnership and adding both scale-up capability and Medical and Scientific Affairs support for Cell IDx customers.

"We are thrilled to welcome Cell IDx to the Leica Biosystems team," said Gustavo Perez-Fernandez, President of Leica Biosystems. "This acquisition will expand our capabilities in the translational research segment and help researchers to accelerate their journey, transforming scientific exploration into translational outcomes."

"The ability to differentiate multiple targets in brightfield has been a long-standing unmet need in clinical pathology. Multiplex chromogenic IHC allows the pathologist to, for example, detect targets inside and outside the tumor. This data on a single tissue section has the potential to inform real time therapy decisions and produce a more focused patient centric approach," said David Schwartz, co-founder and former CEO of Cell IDx. "Getting this technology into the hands of researchers will advance the science of cancer diagnostics and improve lives. We are delighted to be a part of this mission."

"The Cell IDx technology promotes the translation of complex multiplex IHC signatures into manageable three and four biomarker panels that can be automated on Leica Biosystems' BOND RX platform for high quality, reproducible staining," said Robert Monroe, Chief Medical Officer at Leica Biosystems. "We see the pairing of UltraPlex and BOND automation as a platform for the creation of next generation tissue-based diagnostics for better prediction of therapeutic response and tumor behavior."

Related Links:
Leica Biosystems
Cell IDx, Inc. 


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.